ScreenerHero

LIPOLipella Pharmaceuticals Inc. Common Stock

NAS · US · Healthcare · Biotechnology · lipella.com
0.0004USD0.00%Mkt Cap: 1848 $P/E: —

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.85K $
Enterprise Value-1.59M $
Revenue (TTM)389.78K $
Gross Profit-3.08M $
Net Income (TTM)-5.02M $
Revenue/Share0.1280 USD
Last Price0.0004 USD
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA0.29
EV/Revenue-4.08
P/S0.00
P/B0.00
EPS (TTM)-2.26
EPS (Forward)-3.20
52W Range
0.00020% of range0.7100
52W High0.7100 USD
52W Low0.0002 USD
Profitability
Gross Margin-573.65%
Oper. Margin-1387.94%
EBITDA Margin0.00%
Profit Margin-935.25%
ROE-261.34%
ROA-187.60%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.95M $
CapEx (TTM)—
FCF Margin-725.32%
FCF Yield-152986.15%
Net Debt-1.59M $
Net Debt/EBITDA0.29
Balance Sheet
Debt/Equity0.02
Current Ratio3.24
Quick Ratio2.89
Book Value/Sh0.3220 USD
Cash/Share0.4020 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:8
Split DateNov 8, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.62M
Float4.33M
Insiders6.31%
Institutions1.30%
Short Interest
Short Ratio3.3d
Short % Float2.35%
Short % Out.2.24%
Shares Short100.09K
Short (prev mo.)133.45K
Technical
SMA 500.0499 (-99.2%)
SMA 2000.1354 (-99.7%)
Beta1.56
S&P 52W Chg18.16%
Avg Vol (30d)9.55K
Avg Vol (10d)1.36K
Technical Indicators
RSI (14)30.2
MACD-0.0169
MACD Signal-0.0173
MACD Hist.+0.0004
BB Upper0.0502 USD
BB Middle0.0166 USD
BB Lower-0.0170 USD
BB Width404.47%
ATR (14)0.0052 USD
Vol Ratio (20d)0.00x